CytomX Therapeutics, Inc. Share-based Payment Arrangement, Expense
CytomX Therapeutics, Inc. (CTMX) reported Share-based Payment Arrangement, Expense of $4.49 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2023-03-27
- CytomX Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2022-06-30 was $4.49M, a 31.09% increase year-over-year.
- CytomX Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2022-03-31 was $3.37M, a 11.07% increase year-over-year.
- CytomX Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2021-12-31 was $3.54M, a 3.66% increase year-over-year.
- CytomX Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2021-09-30 was $3.16M, a 17.63% decline year-over-year.
- CytomX Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2021 was $13.17M, a 10.95% decline from fiscal 2020.
- CytomX Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2020 was $14.79M, a 22.59% decline from fiscal 2019.
- CytomX Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2019 was $19.10M, a 13.17% increase from fiscal 2018.
- CytomX Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2018 was $16.88M, a 49.53% increase from fiscal 2017.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2022-06-30 | $4.49M 10-Q · filed 2022-08-04 | $7.86M 10-Q · filed 2022-08-04 | $11.40M derived: sum of 3 quarters · filed 2023-03-27 | $14.57M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2022-03-31 | $3.37M 10-Q · filed 2022-05-05 | $6.91M derived: sum of 2 quarters · filed 2023-03-27 | $10.08M derived: sum of 3 quarters · filed 2023-03-27 | $13.50M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-12-31 | $3.54M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $6.71M derived: sum of 2 quarters · filed 2023-03-27 | $10.13M derived: sum of 3 quarters · filed 2023-03-27 | $13.17M 10-K/A · filed 2023-03-27 | |
| 2021-09-30 | $3.16M 10-Q · filed 2021-11-04 | $6.59M derived: sum of 2 quarters · filed 2022-08-04 | $9.62M 10-Q · filed 2021-11-04 | $13.04M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-06-30 | $3.42M 10-Q · filed 2022-08-04 | $6.46M 10-Q · filed 2022-08-04 | $9.88M derived: sum of 3 quarters · filed 2023-03-27 | $13.72M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-03-31 | $3.03M 10-Q · filed 2022-05-05 | $6.45M derived: sum of 2 quarters · filed 2023-03-27 | $10.29M derived: sum of 3 quarters · filed 2023-03-27 | $13.81M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-12-31 | $3.42M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $7.26M derived: sum of 2 quarters · filed 2023-03-27 | $10.77M derived: sum of 3 quarters · filed 2023-03-27 | $14.79M 10-K/A · filed 2023-03-27 | |
| 2020-09-30 | $3.84M 10-Q · filed 2021-11-04 | $7.35M derived: sum of 2 quarters · filed 2021-11-04 | $11.37M 10-Q · filed 2021-11-04 | $15.48M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-06-30 | $3.51M 10-Q · filed 2021-08-05 | $7.53M 10-Q · filed 2021-08-05 | $11.64M derived: sum of 3 quarters · filed 2023-03-27 | $15.98M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-03-31 | $4.01M 10-Q · filed 2021-05-06 | $8.12M derived: sum of 2 quarters · filed 2023-03-27 | $12.47M derived: sum of 3 quarters · filed 2023-03-27 | $17.92M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2019-12-31 | $4.11M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $8.45M derived: sum of 2 quarters · filed 2023-03-27 | $13.91M derived: sum of 3 quarters · filed 2023-03-27 | $19.10M 10-K/A · filed 2023-03-27 | |
| 2019-09-30 | $4.34M 10-Q · filed 2020-11-05 | $9.80M derived: sum of 2 quarters · filed 2020-11-05 | $14.99M 10-Q · filed 2020-11-05 | $19.61M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $5.45M 10-Q · filed 2020-08-06 | $10.65M 10-Q · filed 2020-08-06 | $15.26M derived: sum of 3 quarters · filed 2021-02-24 | $19.68M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $5.19M 10-Q · filed 2020-05-07 | $9.81M derived: sum of 2 quarters · filed 2021-02-24 | $14.22M derived: sum of 3 quarters · filed 2021-02-24 | $18.38M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $9.03M derived: sum of 2 quarters · filed 2021-02-24 | $13.19M derived: sum of 3 quarters · filed 2021-02-24 | $16.88M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $4.41M 10-Q · filed 2019-11-07 | $8.57M derived: sum of 2 quarters · filed 2019-11-07 | $12.26M 10-Q · filed 2019-11-07 | $15.01M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $4.16M 10-Q · filed 2019-08-07 | $7.85M 10-Q · filed 2019-08-07 | $10.60M derived: sum of 3 quarters · filed 2020-02-27 | $13.38M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $3.69M 10-Q · filed 2019-05-09 | $6.44M derived: sum of 2 quarters · filed 2020-02-27 | $9.22M derived: sum of 3 quarters · filed 2020-02-27 | $12.23M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $5.53M derived: sum of 2 quarters · filed 2020-02-27 | $8.54M derived: sum of 3 quarters · filed 2020-02-27 | $11.29M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $2.78M 10-Q · filed 2018-11-06 | $5.79M derived: sum of 2 quarters · filed 2018-11-06 | $8.54M 10-Q · filed 2018-11-06 | $11.00M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $3.01M 10-Q · filed 2018-08-08 | $5.76M 10-Q · filed 2018-08-08 | $8.22M derived: sum of 3 quarters · filed 2019-02-27 | $10.94M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $2.75M 10-Q · filed 2018-05-09 | $5.21M derived: sum of 2 quarters · filed 2019-02-27 | $7.93M derived: sum of 3 quarters · filed 2019-02-27 | $10.32M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $5.18M derived: sum of 2 quarters · filed 2019-02-27 | $7.57M derived: sum of 3 quarters · filed 2019-02-27 | $10.10M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $2.72M 10-Q · filed 2017-11-07 | $5.11M derived: sum of 2 quarters · filed 2017-11-07 | $7.63M 10-Q · filed 2017-11-07 | $9.39M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-06-30 | $2.39M 10-Q · filed 2017-08-07 | $4.91M 10-Q · filed 2017-08-07 | $6.67M derived: sum of 3 quarters · filed 2018-03-07 | $8.02M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-03-31 | $2.36M 10-Q · filed 2017-05-05 | $2.52M 10-Q · filed 2016-05-06 | $4.28M derived: sum of 2 quarters · filed 2018-03-07 | $5.63M derived: sum of 3 quarters · filed 2018-03-07 | $6.17M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $3.27M derived: sum of 2 quarters · filed 2018-03-07 | $3.81M derived: sum of 3 quarters · filed 2018-03-07 | $3.99M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $1.34M 10-Q · filed 2016-11-03 | $1.89M derived: sum of 2 quarters · filed 2016-11-03 | $2.06M 10-Q · filed 2016-11-03 | $2.21M derived: sum of 4 quarters · filed 2017-03-02 | |
| 2015-06-30 | $546.00K 10-Q · filed 2016-08-03 | $721.00K 10-Q · filed 2016-08-03 | $865.00K derived: sum of 3 quarters · filed 2017-03-02 | $1.03M derived: sum of 4 quarters · filed 2017-03-02 | |
| 2015-03-31 | $175.00K 10-Q · filed 2016-05-06 | $319.00K derived: sum of 2 quarters · filed 2017-03-02 | $483.00K derived: sum of 3 quarters · filed 2017-03-02 | ||
| 2014-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $308.00K derived: sum of 2 quarters · filed 2017-03-02 | $553.00K 10-K · filed 2017-03-02 | ||
| 2014-09-30 | $164.00K 10-Q · filed 2015-11-23 | $409.00K 10-Q · filed 2015-11-23 | |||
| 2013-12-31 | $343.00K 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |